Synaptogenix Inc (SNPX)

[Antti]

Yes, no double-blind, no placebo and no proper randomization either. On slide 12, patients having higher dosage had much higher baseline MMSE. That wouldn't have happened if they would have randomized the patients correctly.

So their entire dosage response hypotheses is based on cherry picking the right patients to high dose group. And that's all the "good" clinical data they have. The rest of it just points to the drug being a placebo since 75% of patients either dropped out or had progression similar to a placebo curve.

https://www.anavex.com/wp-content/uploads/2019/03/ANAVEX2-73_CTAD_2018_Presentation.pdf